Show simple item record

dc.contributor.authorMullen, Lisa
dc.contributor.authorRigby, Anne
dc.contributor.authorSclanders, Michelle
dc.contributor.authorAdams, Gill
dc.contributor.authorMittal, Gayatri
dc.contributor.authorColston, Julia
dc.contributor.authorFatah, Rewas
dc.contributor.authorSubang, Cristina
dc.contributor.authorFoster, Julie
dc.contributor.authorFrancis-West, Philippa
dc.contributor.authorKöster, Mario
dc.contributor.authorHauser, Hansjörg
dc.contributor.authorLayward, Lorna
dc.contributor.authorVessillier, Sandrine
dc.contributor.authorAnnenkov, Alex
dc.contributor.authorAl-Izki, Sarah
dc.contributor.authorPryce, Gareth
dc.contributor.authorBolton, Chris
dc.contributor.authorBaker, David
dc.contributor.authorGould, David J
dc.contributor.authorChernajovsky, Yuti
dc.date.accessioned2014-05-13T08:18:00Z
dc.date.available2014-05-13T08:18:00Z
dc.date.issued2014-01
dc.identifier.citationLatency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. 2014, 11 (1):5-16 Expert Opin Drug Deliven
dc.identifier.issn1744-7593
dc.identifier.pmid24073618
dc.identifier.doi10.1517/17425247.2013.839655
dc.identifier.urihttp://hdl.handle.net/10033/316733
dc.description.abstractTargeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent-associated peptide (LAP) derived from TGF-β with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation. The aim of this study is to determine whether this approach can be applied to cytokines of different molecular structures and sizes.
dc.language.isoenen
dc.rightsArchived with thanks to Expert opinion on drug deliveryen
dc.titleLatency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.en
dc.typeArticleen
dc.contributor.departmentExperimental Rheumatology, Charité University Medicine, Berlin, Germanyen
dc.identifier.journalExpert opinion on drug deliveryen
refterms.dateFOA2015-01-15T00:00:00Z
html.description.abstractTargeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent-associated peptide (LAP) derived from TGF-β with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation. The aim of this study is to determine whether this approach can be applied to cytokines of different molecular structures and sizes.


Files in this item

Thumbnail
Name:
Mullen et al_final.pdf
Size:
376.9Kb
Format:
PDF
Description:
original manuscript
Thumbnail
Name:
Figure 1.tif
Size:
354.8Kb
Format:
TIFF image
Description:
figure 1
Thumbnail
Name:
Figure 2A-D.tif
Size:
1.310Mb
Format:
TIFF image
Description:
figues 2 A to D
Thumbnail
Name:
Figure 2E-H.tif
Size:
2.499Mb
Format:
TIFF image
Description:
figures 2 E to H
Thumbnail
Name:
Figure 3.tif
Size:
324.5Kb
Format:
TIFF image
Description:
figure 3
Thumbnail
Name:
Figure 3C-D.tif
Size:
545.3Kb
Format:
TIFF image
Description:
figures 3 C to D
Thumbnail
Name:
Figure 3E-F.tif
Size:
275.3Kb
Format:
TIFF image
Description:
figures 3 E to F
Thumbnail
Name:
Figure 3G-H.tif
Size:
1.042Mb
Format:
TIFF image
Description:
figues 3 G to H
Thumbnail
Name:
Figure 4.tif
Size:
693.2Kb
Format:
TIFF image
Description:
figure 4
Thumbnail
Name:
Figure 5.tif
Size:
1.746Mb
Format:
TIFF image
Description:
figure 5

This item appears in the following Collection(s)

Show simple item record